Why Stock Analysts Take Notice of Momenta Pharmaceuticals Inc.’s (MNTA) Business Progress
This stock is an unusual case of exceptional inherent value. The company is yet to enter the commercial and profitable phases of its business. The stock price has more than doubled on the last day of this leap year’s February, compared to its 52-week low. At least one highly respected stock market analyst has vaulted the stock to the outperform category. Investors need to appreciate the pharmaceutical industry developmental process, to value this stock correctly. It is a case in which financial expertise is not enough by itself. The company has been formed around a novel technology. This consists of…